
“External environmental factors such as the spread of COVID-19 and the war between Ukraine and Russia have made domestic drug supply and demand abnormal.
On January 15, Korea Rare Essential Medicines Center appointed Kim Jin-seok (58, Kyungsung University College of Medicine), former deputy director of the Ministry of Food and Drug Safety, as the 13th director.
The KODC, which was established to provide various information on orphan drugs and national essential drugs, is currently managing 511 items of national essential drugs and 315 cases of orphan and essential drugs submitted to the on-site supply and demand monitoring center.
A total of 179 items and 14,732 drugs were supplied by the KODC last year, worth 44.2 billion won.
Nine free support programs that connect pharmaceutical companies and patients are also in operation, through which 969 new drugs in clinical trials were supplied.
Director Kim met with reporters from the Ministry of Food and Drug Safety on the 21st and revealed his ambition to be appointed director of the KODC after 8 months of vacancy.
The following is a Q&A from Director Kim.
▶ As the director was appointed after 8 months of vacancy, it seems that there was a setback in the project.
"There was a long hiatus for eight months after the former director's resignation.
During this period, there was a shortage of medicines around the world due to the outbreak of COVID-19 and monkeypox.
Korea was no exception, and monitoring of essential national medicines and supply shortages of medicines occurred.
We are aware of the need for a domestic supply of drugs, so this year we plan to focus our efforts on the stable supply of national essential medicines.
As in the case of last year’s case where the center urgently imported from Australia to solve the domestic shortage of antipyretics and analgesics due to COVID-19, domestic We will develop our capacity so that the center can play a big role in the stable supply of medicines.” ▶ Please explain the promotion project in a little more detail.
“As revealed in the name of the center, the primary goal is to supply medicines that have lost their market function, such as orphan drugs and national essential medicines, from state institutions.
Whether it is an orphan drug, an essential drug, or a drug with usage monitoring, a situation in which supply and demand arise means that the function of the market appears in an abnormal situation.
It depends on whether or not, but for orphan drugs, at least a network is built with data on suppliers and countries.
This year, it plans to build an information network for essential medicines and medicines that require on-site supply and demand monitoring.
The Ministry of Food and Drug Safety signed a contract for a consignment project to build an information network last week.
Internally, a program is being developed to increase the accuracy of usage statistics for essential medicines.
We will complete it within this year so that production and usage can be predicted based on statistical data.
" ▶ Recently, there have been cases of drug price adjustments due to shortages, and we know that orphan essential drugs have the biggest concern about profitability.
Are there separate studies in this regard?
“Because the center is a non-profit corporation under the Ministry of Food and Drug Safety and does not operate a profit-making business, there is no need to adjust the price of medicines supplied by the center due to a shortage of medicines.
There was a case that this center that had an impact on the drug price.
Last year, the drug price of 'Natasin Eye Suspension' was adjusted due to the increase in the unit price of medicine." ▶Please explain the on-site drug supply and demand monitoring project.
“The center is operating an on-site supply and demand monitoring center with 7 professional organizations, including the Korea Hospital Pharmacists Association, the Korean Medical Association, the Korean Pharmaceutical Association, the Korea Pharmaceutical and Biopharmaceutical Association, the Global Pharmaceutical Industry Association, the Korea Biopharmaceutical Association, and the Korea Pharmaceutical Distribution Association.
Each organization When a request for medicines in need of supply is made through expert consultation, supply-related issues are informed and solutions are sought.” ▶The budget for the center increased from 3.3 billion won last year to 4.6 billion won this year.
How will the increased budget be used?
“The main items of the center’s increased budget this year are 490 million won for consignment manufacturing and 600 million won for office relocation, and isoproterenol hydrochloride injection will be introduced as a new consignment manufacturing item to address the need for a stable supply of medicines that have been continuously raised.” We plan to move the center to the Post Tower adjacent to Myeongdong Station in June.
The building located along the main road will make it more convenient for users of the center." ▶At the plenary meeting of the Health and Welfare Committee of the National Assembly held on the 9th, it was pointed out that it is necessary to secure personnel exclusively responsible for monitoring the supply and demand situation of medicines in the Korea Rare Essential Drug Center and to establish a close cooperation system with medical and pharmaceutical organizations.
"This year, we plan to strengthen the monitoring of discontinued medicines through the administrative network linked to the Ministry of Food and Drug Safety by further activating the operation of the on-site drug supply and demand monitoring network.
In particular, actively promote two-way communication between supply and demand monitoring networks through real-time information sharing with 7 specialized organizations Through this, we intend to strengthen the monitoring of unstable supply together.”
댓글 운영방식은
댓글은 실명게재와 익명게재 방식이 있으며, 실명은 이름과 아이디가 노출됩니다. 익명은 필명으로 등록 가능하며, 대댓글은 익명으로 등록 가능합니다.
댓글 노출방식은
댓글 명예자문위원(팜-코니언-필기모양 아이콘)으로 위촉된 데일리팜 회원의 댓글은 ‘게시판형 보기’와 ’펼쳐보기형’ 리스트에서 항상 최상단에 노출됩니다. 새로운 댓글을 올리는 일반회원은 ‘게시판형’과 ‘펼쳐보기형’ 모두 팜코니언 회원이 쓴 댓글의 하단에 실시간 노출됩니다.
댓글의 삭제 기준은
다음의 경우 사전 통보없이 삭제하고 아이디 이용정지 또는 영구 가입제한이 될 수도 있습니다.
저작권·인격권 등 타인의 권리를 침해하는 경우
상용 프로그램의 등록과 게재, 배포를 안내하는 게시물
타인 또는 제3자의 저작권 및 기타 권리를 침해한 내용을 담은 게시물
근거 없는 비방·명예를 훼손하는 게시물
특정 이용자 및 개인에 대한 인신 공격적인 내용의 글 및 직접적인 욕설이 사용된 경우
특정 지역 및 종교간의 감정대립을 조장하는 내용
사실 확인이 안된 소문을 유포 시키는 경우
욕설과 비어, 속어를 담은 내용
정당법 및 공직선거법, 관계 법령에 저촉되는 경우(선관위 요청 시 즉시 삭제)
특정 지역이나 단체를 비하하는 경우
특정인의 명예를 훼손하여 해당인이 삭제를 요청하는 경우
특정인의 개인정보(주민등록번호, 전화, 상세주소 등)를 무단으로 게시하는 경우
타인의 ID 혹은 닉네임을 도용하는 경우
게시판 특성상 제한되는 내용
서비스 주제와 맞지 않는 내용의 글을 게재한 경우
동일 내용의 연속 게재 및 여러 기사에 중복 게재한 경우
부분적으로 변경하여 반복 게재하는 경우도 포함
제목과 관련 없는 내용의 게시물, 제목과 본문이 무관한 경우
돈벌기 및 직·간접 상업적 목적의 내용이 포함된 게시물
게시물 읽기 유도 등을 위해 내용과 무관한 제목을 사용한 경우
수사기관 등의 공식적인 요청이 있는 경우
기타사항
각 서비스의 필요성에 따라 미리 공지한 경우
기타 법률에 저촉되는 정보 게재를 목적으로 할 경우
기타 원만한 운영을 위해 운영자가 필요하다고 판단되는 내용
사실 관계 확인 후 삭제
저작권자로부터 허락받지 않은 내용을 무단 게재, 복제, 배포하는 경우
타인의 초상권을 침해하거나 개인정보를 유출하는 경우
당사에 제공한 이용자의 정보가 허위인 경우 (타인의 ID, 비밀번호 도용 등)
※이상의 내용중 일부 사항에 적용될 경우 이용약관 및 관련 법률에 의해 제재를 받으실 수도 있으며, 민·형사상 처벌을 받을 수도 있습니다.
※위에 명시되지 않은 내용이더라도 불법적인 내용으로 판단되거나 데일리팜 서비스에 바람직하지 않다고 판단되는 경우는 선 조치 이후 본 관리 기준을 수정 공시하겠습니다.
※기타 문의 사항은 데일리팜 운영자에게 연락주십시오. 메일 주소는 dailypharm@dailypharm.com입니다.